Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study

Hidetoshi Yasuoka\textsuperscript{a} Atsushi Naganuma\textsuperscript{a} Eishin Kurihara\textsuperscript{b} Tsutomu Kobatake\textsuperscript{b} Masashi Ijima\textsuperscript{b} Yuki Tamura\textsuperscript{a} Yuhei Suzuki\textsuperscript{a} Takashi Hoshino\textsuperscript{a} Fumiya Ishida\textsuperscript{c} Hisashi Hosaka\textsuperscript{d} Takeshi Hatanaka\textsuperscript{e} Sachiko Yoshida\textsuperscript{e} Ryusuke Aihara\textsuperscript{f} Yasuo Hosouchi\textsuperscript{f} Norihiro Ishii\textsuperscript{g} Kenichiro Araki\textsuperscript{g} Ken Shirabe\textsuperscript{g} Toshio Uraoka\textsuperscript{h} Satoru Kakizaki\textsuperscript{a,c,h}

\textsuperscript{a}Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan; \textsuperscript{b}Department of Gastroenterology, SUBARU Ota Memorial Hospital, Ota, Japan; \textsuperscript{c}Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan; \textsuperscript{d}Division of Gastroenterological Medicine, Gunma Prefectural Cancer Center, Ota, Japan; \textsuperscript{e}Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan; \textsuperscript{f}Department of Surgery, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan; \textsuperscript{g}Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan; \textsuperscript{h}Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan

Keywords
Nano-liposomal irinotecan · Unresectable advanced pancreatic cancer · Second-line treatment · Real-world data

**Abstract**

**Introduction:** This retrospective study investigated the efficacy and safety of nano-liposomal irinotecan (nal-IRI) plus 5-fluorouracil/L-leucovorin (5-FU/L-LV) treatment in the second-line or later setting for advanced pancreatic cancer under real-world conditions. **Methods:** Between June 2020 and September 2021, a total of 44 patients with unresectable advanced pancreatic cancer treated with nal-IRI + 5-FU/L-LV in our affiliated hospitals were included. The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated. **Results:** The median age was 68 (interquartile range 62–73) years old, and 22 patients (50.0%) were male. Concerning tumor factors, 9 patients (20.5%) had local advanced disease and 35 patients (79.5%) had metastases. Twenty-five of the 44 patients were receiving second-line treatment, and 19 were receiving third-line or later treatment. The median overall survival (OS) and progression-free survival were 9.0 (range, 0.7–15.4) months and 4.4 (range, 0.6–15.4) months, respectively. The overall response rate was 5.3%. The disease control rate was 44.7%. Patients with a neutrophil-to-lymphocyte ratio of ≥2.7 had a significant risk of a poor OS (HR = 0.275, \(p = 0.017\)). Adverse events were
manageable, although gastrointestinal symptoms and neutropenia were observed. The most common grade ≥3 adverse event was neutropenia, which was reported in 20% of patients. **Conclusions:** Nal-IRI + 5-FU/l-LV therapy was considered to be a useful regimen as second-line or later treatment for unresectable advanced pancreatic cancer, even in clinical practice.

**Introduction**

Despite recent advances in diagnostic technology and anticancer drugs, pancreatic cancer continues to have a poor prognosis worldwide [1]. It is the fourth leading cause of cancer-related death in the USA and Japan [1, 2]. Approximately 70–90% of patients with pancreatic cancer are diagnosed at an advanced stage, and the 5-year overall survival (OS) rate is only 8–11% [3–5].

As first-line treatment for advanced pancreatic cancer, combination therapy with gemcitabine plus nab-paclitaxel (GEM + Nab-PTX) or folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX) has shown a survival benefit compared to gemcitabine monotherapy [6, 7]. However, the OS with first-line treatment remains less than 1 year on average [6, 7]. Similarly, the progression-free survival (PFS) for the recommended first-line regimens, such as gemcitabine, GEM + Nab-PTX, and FOLFIRINOX, are only 3.4, 5.5, and 6.4 months, respectively [6–8]. As a result, most patients require second-line or later regimens.

Nano-liposomal irinotecan (nal-IRI) consists of pegylated liposomes containing irinotecan sucrosephate salt, a topoisomerase I inhibitor [9, 10]. Liposomal encapsulation reduces premature liver metabolism and conversion of irinotecan to the highly active SN-38 metabolite [9, 10]. Nal-IRI exhibits a lower maximum concentration of free irinotecan in plasma, a longer half-life and a greater area under the curve in plasma for SN-38 [9, 10] than non-liposomal irinotecan [9, 10]. This prolongs tumor exposure to SN-38 above its antitumor activity threshold and increases the SN-38 levels in tumor tissue compared with plasma [9, 10].

The phase III NAPOLI-1 trial demonstrated a better median OS with nal-IRI + 5-FU/l-leucovorin (5-FU/l-LV) than with 5-FU/l-LV (6.1 months vs. 4.2 months) [11, 12]. A phase II trial in Japan also demonstrated a similar median OS of 6.3 months for nal-IRI + 5-FU/l-LV with a tolerable safety profile [13]. In Japan, this combination therapy has been available since June 2020 in the real-world setting. Therefore, there is limited post-approval real-world data regarding its efficacy, safety, and optimal sequencing in Japan. The NAPOLI-1 trial only enrolled patients who failed prior gemcitabine-based therapy.

Given the above, the present study investigated the efficacy and safety of nal-IRI + 5-FU/l-LV treatment under real-world conditions in Japanese patients. The predictive factors, including systemic inflammation-based prognostic indicators, were investigated.

**Materials and Methods**

**Patients**

Between June 2020 and September 2021, a total of 44 Japanese patients with advanced pancreatic cancer receiving nal-IRI + 5-FU/l-LV treatment at the Takasaki General Medical Center and its affiliated hospitals were included, and none were excluded from the current retrospective study. Patients were diagnosed with pancreatic cancer based on typical radiological findings or pathological findings. The authors retrospectively examined the medical records, collected patient characteristics and analyzed the outcomes, including the tumor response, OS, PFS, and adverse events (AEs).

Nal-IRI + 5-FU/l-LV treatment and the assessment of the tumor response and AEs. Nal-IRI (80 mg/m²) was administered by intravenous infusion over 90 ± 10 min, followed by 200 mg/m² 1-LV via intravenous infusion over 2 h and then 2,400 mg/m² 5-FU via intravenous infusion over 46 ± 3 h, every 2 weeks. During screening, patients were tested for the presence of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1)*28 and UGT1A1*6 alleles to determine the starting dose for nal-IRI. A patient found to be homozygous with UGT1A1*28 or UGT1A1*6 or double heterozygous received a reduced starting dose of nal-IRI (60 mg/m²). Treatment continued until the appearance of disease progression or unacceptable AEs.

Contrast-enhanced computed tomography or magnetic resonance imaging was carried out every 4–8 weeks. The tumor response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The overall response rate (ORR) was defined as the sum of the complete response (CR), and partial response (PR). The disease control rate (DCR) was defined as the sum of the CR, PR, and stable disease rates. The OS was defined as the period from the day of initial nal-IRI + 5-FU/l-LV treatment to the day of death or last visit. The PFS was defined as the period from the day of initial nal-IRI + 5-FU/l-LV treatment to the day of the presence of disease progression or death.

The performance status was evaluated by the Eastern Cooperative Oncology Group [14]. AEs related to nal-IRI + 5-FU/l-LV treatment were assessed by the Common Terminology Criteria for Adverse Events version 5.0 [15]. The serum levels of CEA and CA19-9 were measured at baseline. The modified Glasgow Prognostic Score (mGPS) was determined as described previously [16, 17]. Patients were stratified into 3 mGPS groups: mGPS 0 (CRP ≤0.5 and albumin ≥3.5 g/dL), mGPS 1 (CRP >0.5 mg/L or albumin <3.5 g/dL), and mGPS 2 (CRP >0.5 mg/L and albumin <3.5 g/dL). The neutrophil-to-lymphocyte ratio (NLR) [18], platelet-to-lymphocyte ratio (PLR), and CRP/Alb ratio were calculated. The prog-
nestic nutritional index (PNI) was calculated as follows: PNI = (10 × serum albumin [g/dL]) + (0.005 × total lymphocyte count [/mm³]). These values were calculated immediately before the administration of nal-IRI + 5-FU/l-LV. We also calculated the NLR at the time of the pancreatic cancer diagnosis.

**Statistical Analyses**

Categorical variables are presented as numbers and percentages, and continuous variables are presented as the median (interquartile range [IQR]). Differences between groups were analyzed by Fisher’s exact probability test and the Mann-Whitney U test when a significant difference was obtained by the Kruskal-Wallis test. The prognosis was assessed using a Cox hazard analysis, the Kaplan-Meier method and a log-rank test. All statistical analyses were performed using the IBM SPSS (Statistics Package for Social Sciences) Statistics 25 software program (Chicago, IL, USA). p values of <0.05 were considered to indicate statistical significance.

**Results**

Patient characteristics are summarized in Table 1. The median age of all patients was 68 (IQR, 62–73) years old, and there were 22 (50.0%) men. The median body mass index before nal-IRI + 5-FU/l-LV treatment was 21.1 (IQR: 19.4–23.8) kg/m². The median body mass index before first-line treatment was 21.5 (IQR: 19.4–25.1) kg/m². The body weight ratio (before nal-IRI + 5-FU/l-LV before first-line treatment) was 98.1% (IQR: 91.3–101.5%). Concerning tumor factors, 9 patients (20.5%) had local advanced disease, and 35 patients (79.5%) had metastases. The PS was 0, 1 and 2 in 17 (38.6%), 24 (54.6%) and 3 patients (6.8%), respectively. The serum levels of CEA and CA19-9 at baseline were 9.4 (IQR, 3.9–48.4) ng/mL and 1,585 (IQR, 121–6,264) U/mL, respectively. A history of first-line treatment with GEM + Nab-PTX, mFOL-FIRINOX and S-1 was noted in 37 (84.1%), 2 (4.5%) and 5 patients (11.4%), respectively. Twenty-five (56.8%), 13 (29.5%), 4 (9.1%), 1 (2.3%), 1 patient (2.3%) received nal-IRI + 5-FU/l-LV treatment as 2nd-, 3rd-, 4th-, 5th-, and 6th-line treatment, respectively. Sixteen (38.1%) of the 42 tested patients were positive for UGT1A1 polymorphism. Among these 16 patients, 6 patients were poor metabolizer and needed to have the starting dose of nal-IRI reduced to 60 mg/m². These 6 patients included 2 patient with UGT1A1*6/*6, two with UGT1A1*28/*28 and two with UGT1A1*6/*28.

**The OS and PFS**

In the analysis of the OS, events occurred in 26 patients (59.1%), with a median follow-up period of 7.2 months (95% confidence interval [CI] 6.0–8.4 months). The Kaplan-Meier curve showed that the median OS of all patients was 9.0 months (95% CI 7.10–10.91 months; Fig. 1a). Figure 1b shows the PFS of all patients. Events were observed in 36 patients (81.8%) in the analysis of the PFS. The median PFS in all patients was estimated to be 4.4 (95% CI 2.4–6.4) months. The PFS in the patients treated with nal-IRI + 5-FU/l-LV as 2nd-line treatment (median 4.4 months; 95% CI 2.1–6.8 months) was not

| Table 1. Patients’ baseline characteristics |
|--------------------------------------------|
| **Characteristics** | **Number (%) or median (IQR)** |
| Patients, n (%) | 44 (100) |
| Sex, n (%) |  |
| Male | 22 (50.0) |
| Female | 22 (50.0) |
| Age, years (IQR) | 68 (62–73) |
| BMI, kg/m² (IQR) | 21.1 (19.4–23.8) |
| Cancer stage, n (%) |  |
| Local/locally advanced | 9 (20.5) |
| Metastatic | 35 (79.5) |
| Performance status |  |
| 0/1/2 | 0/1/2 |
| Alb, g/dL (IQR) | 3.6 (3.3–3.8) |
| CRP (IQR) | 0.33 (0.14–0.88) |
| mGPS (%) | 2nd |
| 0/1/2 | 18 (40.9)/18 (40.9)/8 (18.2) |
| NLR (IQR) | 3.45 (2.64–5.08) |
| PLR (IQR) | 182.8 (141.7–247.8) |
| CRP/Alb ratio (IQR) | 0.09 (0.03–0.28) |
| PNI (IQR) | 41.7 (38.7–44.6) |
| CEA (IQR) | 9.4 (3.9–48.4) |
| CA19-9 (IQR) | 1,585 (121–6,264) |
| Line of therapy at which nal-IRI + 5-FU/l-LV was administered (%) |  |
| 2nd | 25 (56.8) |
| 3rd | 13 (29.5) |
| 4th | 4 (9.1) |
| 5th | 1 (2.3) |
| 6th | 1 (2.3) |
| First-line cancer therapy (%) |  |
| GEM + Nab-PTX | 37 (84.1) |
| mFOL-FIRINOX | 2 (4.5) |
| S-1 | 5 (11.4) |
| UGT1A1 status (%) |  |
| Wild type | 26 (59.1) |
| Non-wild, non-poor metabolizer | 10 (22.7) |
| Non-wild, poor metabolizer | 6 (13.6) |
| Not tested | 2 (4.5) |

IQR, interquartile range; BMI, body mass index; Alb, albumin; mGPS, modified Glasgow Prognostic Score; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; GEM, gemcitabine; Nab-PTX, nab-paclitaxel, mFOL-FIRINOX, modified FOLFIRINOX; UGT, uridine diphosphate glucuronosyltransferase.
significantly different from that in those treated with nal-IRI + 5-FU/l-LV as 3rd-line or later treatment (median 4.4 months; 95% CI 0.8–8.0 months; \( p = 0.583 \)).

Figure 2 shows the Kaplan-Meier curve of the OS according to the systemic inflammation-based prognostic indicators. The patients with an NLR < 2.7 (median, not reached) had a significantly better survival than those with an NLR \( \geq 2.7 \) (median 6.0 months; 95% CI 4.98–6.95 months; \( p = 0.002 \); Fig. 2b). The patients with a CRP/Alb ratio < 0.3 (median 9.8 months; 95% CI 7.82–11.71) also had a significantly better survival than those with a CRP/Alb ratio \( \geq 0.3 \) (median 5.1 months; 95% CI 0.0–10.31 months; \( p = 0.017 \); Fig. 2d). There were no significant differences in the OS regarding the mGPS score, PLR, or PNI. The OS in the patients treated with nal-IRI + 5-FU/l-LV as 2nd-line treatment (median 9.0 months; 95% CI 6.2–11.8 months) was not significantly different from that in those treated with nal-IRI + 5-FU/l-LV as 3rd-line or later treatment (median 8.2 months; 95% CI 2.5–14.0 months; \( p = 0.802 \)). Because the NLR calculated before the administration of nal-IRI + 5-FU/l-LV was a significant predictive factor for the prognosis, we also calculated the NLR at the time of the pancreatic cancer diagnosis (online suppl. Fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000525742). Five cases were missing data. Although the patients with an NLR of < 2.7 (median 13.3 months; 95% CI 3.8–22.8 months) at the time of the pancreatic cancer diagnosis tended to have

---

**Fig. 1.** a The OS with nal-IRI + 5-FU/l-LV. The Kaplan-Meier curve showed that the median OS of all patients was 9.0 months. b The PFS with nal-IRI + 5-FU/l-LV. The median PFS in all patients was estimated to be 4.4 months.

**Fig. 2.** The Kaplan-Meier curve according to the systemic inflammation-based prognostic indicators and lines of treatment. a The mGPS. There were no significant differences between the patients with an mGPS score 0 (median OS, 10.3 months; 95% CI, 9.31–11.29) and those with an mGPS score 1 + 2 (median OS, 6.8 months; 95% CI, 3.36–10.24; \( p = 0.137 \)). b The NLR. The patients with an NLR < 2.7 had a significantly better survival (median OS, not reached) than those with an NLR \( \geq 2.7 \) (median OS, 6.0 months; 95% CI, 4.98–6.95; \( p = 0.002 \)). c The platelet-to-lymphocyte ratio (PLR). There were no significant differences between the patients with a PLR < 155 (median OS, 9.8 months; 95% CI, 7.60–11.93) and those with a PLR \( \geq 155 \) (median OS, 6.8 months; 95% CI, 3.52–10.08; \( p = 0.486 \)). d CRP/Alb ratio. The patients with a CRP/Alb ratio < 0.3 also had a significantly better survival (median OS, 9.8 months; 95% CI, 7.82–11.71) than those with a CRP/Alb ratio \( \geq 0.3 \) (median OS, 5.1 months, 95% CI, 0.0–10.31; \( p = 0.017 \)). e The PNI. There were no significant differences between the patients with a PNI > 40 (median OS, 9.8 months; 95% CI, 8.28–11.39) and those with a PNI \( \leq 40 \) (median OS, 5.7 months; 95% CI, 3.12–8.35; \( p = 0.205 \)). f Line of treatment. There were no significant differences between the patients who received nal-IRI + 5-FU/l-LV as 2nd-line treatment (median 9.0 months; 95% CI 6.2–11.8 months) and those treated with nal-IRI + 5-FU/l-LV as 3rd-line or later treatment (median 8.2 months; 95% CI 2.5–14.0 months; \( p = 0.802 \)).

(For figure see next page.)
Nal-IRI + 5-FU/l-LV in Advanced Pancreatic Cancer

Survival rate

### mGPS

- **0**
- **1, 2**

\[ p = 0.137 \]

Number at risk

- mGPS 0: 18, 14, 6, 0, 0
- mGPS 1, 2: 26, 16, 4, 1, 0

### NLR

- NLR <2.7: 14, 12, 7, 1, 0
- NLR ≥2.7: 30, 18, 3, 16, 0

\[ p = 0.002 \]

\[ p = 0.002 \]

### PLR

- PLR <155: 13, 10, 3, 0, 0
- PLR ≥155: 31, 20, 7, 1, 0

\[ p = 0.486 \]

\[ p = 0.017 \]

### CRP/Alb ratio

- CRP/Alb ratio <0.3: 24, 10, 1, 0, 0
- CRP/Alb ratio ≥0.3: 11, 6, 1, 0, 0

\[ p = 0.017 \]

\[ p = 0.802 \]

### PNI

- PNI >40: 28, 20, 8, 0, 0
- PNI ≤40: 16, 10, 2, 1, 0

\[ p = 0.205 \]

\[ p = 0.802 \]

### Line

- 2nd line: 25, 17, 5, 0, 0
- 3rd or later: 19, 13, 5, 0, 0

\[ p = 0.802 \]
(For legend see next page.)
better survival than those with an NLR $\geq 2.7$ (median 6.8 months; 95% CI 2.7–10.9 months), the difference did not reach the statistical significance ($p = 0.083$).

Online supplementary Figure 2 shows the PFS of earlier line treatment before nal-IRI + 5-FU/l-LV treatment. In the 24 patients treated with nal-IRI + 5-FU/l-LV as 2nd-line treatment, the median PFS of patients who received 1st-line treatment with GEM + Nab-PTX was 5.3 months (95% CI 4.4–6.1 months). The median OS of patients who received nal-IRI + 5-FU/l-LV as 2nd-line treatment was 9.0 months (95% CI 6.2–11.8 months). In the 13 patients treated with nal-IRI + 5-FU/l-LV as 3rd-line treatment, the median PFS of patients who received 1st-line and 2nd-line treatment were 6.7 months (95% CI 3.9–9.6 months) and 6.7 months (95% CI 0.8–12.7), respectively. The median OS of patients who received nal-IRI + 5-FU/l-LV as 3rd-line treatment was 6.5 months (95% CI 1.2–11.8 months). First-line treatment included 8 patients with GEM + Nab-PTX, 4 patients with S-1, and 1 patient treated with mFOLFIRINOX. Second-line treatment included 5 patients treated with GEM + Nab-PTX, 4 patients treated with mFOLFIRINOX, 3 patients treated with S-1, and 1 patient treated with gemcitabine. The 6 patients treated with nal-IRI + 5-FU/l-LV as 4th-line or later treatment were excluded from this analysis. Although the PFS during 1st-line treatment in the patients with nal-IRI + 5-FU/l-LV as 3rd-line treatment tended to be better than in comparison to the patients who received nal-IRI + 5-FU/l-LV as 2nd-line treatment, the difference in PFS with 1st-line treatment was not statistically significant (online suppl. Fig. 2).

Figure 3 shows the receiver operator characteristic analyses for the OS at the 6-month follow-up. The NLR (Fig. 3b, $p = 0.019$) and CRP/Alb ratio (Fig. 3d, $p = 0.028$) were significantly associated with the OS at the 6-month follow-up, whereas the mGPS, PLR, and PNI did not influence the OS at the 6-month follow-up. The area under the curve (AUC) of variables was as follows: mGPS, 0.656 (95% CI 0.478–0.835, $p = 0.086$); NLR, 0.726 (95% CI 0.578–0.876, $p = 0.019$); PLR, 0.568 (95% CI 0.391–0.745, $p = 0.45$); CRP/Alb ratio, 0.701 (95% CI 0.521–0.881, $p = 0.028$); PNI, 0.600 (95% CI 0.399–0.802, $p = 0.327$).

Online supplementary Figure 3 shows the Kaplan-Meier curve of the OS and PFS according to the UGT1A1 polymorphism. The OS in the patients with UGT1A1 non-poor metabolizer (median 9.0 months; 95% CI 7.2–10.9 months) was not significantly different from that in those with UGT1A1 poor metabolizer (median 4.1 months; 95% CI 0.0–10.9 months; $p = 0.201$; online suppl. Fig. 3a). The PFS in the patients with UGT1A1 non-poor metabolizer (median 4.4 months; 95% CI 1.8–7.1 months) was not significantly different from that in those with UGT1A1 poor metabolizer (median 2.0 months; 95% CI 0.0–6.0 months; $p = 0.571$; online suppl. Fig. 3b). Although it did not reach the statistical significances, the OS and PFS in the patients with UGT1A1 poor metabolizer tended to be worse than in comparison to the patients with UGT1A1 non-poor metabolizer. However, we cannot get the conclusive results because of small number of UGT1A1 poor metabolizer.

The ORR and DCR

The results associated with the tumor response are shown in Table 2. According to the RECIST, 2 patients (4.5%) had PR, 15 (34.1%) had stable disease (SD), 21 (47.8%) had PD, and 6 patients (13.6%) were not evaluable, while no patients had CR. Thus, the ORR and DCR in all patients were calculated to be 5.3% (2/38) and 44.7% (17/38), respectively.

Factors Predicting the OS according to Univariate and Multivariate Analyses

Table 3 shows predictive factors associated with the OS in patients treated with nal-IRI + 5-FU/l-LV by univariate

![Fig. 3. Receiver operator characteristic analyses for the OS at 6-month follow-up. The mGPS (a), NLR (b), platelet-to-lymphocyte ratio (PLR) (c), CRP/Alb ratio (d) and PNI (e). The area under the curve (AUC) of variables was as follows: mGPS, 0.656 (95% CI 0.478–0.835, $p = 0.086$); NLR, 0.726 (95% CI 0.578–0.876, $p = 0.019$); PLR, 0.568 (95% CI 0.391–0.745, $p = 0.45$); CRP/Alb ratio, 0.701 (95% CI 0.521–0.881, $p = 0.028$); PNI, 0.600 (95% CI 0.399–0.802, $p = 0.327$). The NLR and CRP/Alb ratio were significantly associated with the OS at 6-month follow-up, while the mGPS, PLR, and PNI did not influence the OS at 6-month follow-up.

![Table 2. The overall response and DCRs](image)

|                | All patients ($n = 44$) |
|----------------|------------------------|
| **CR, n (%)**  | 0 (0)                  |
| **PR, n (%)**  | 2 (4.5)                |
| **SD, n (%)**  | 15 (34.1)              |
| **PD, n (%)**  | 21 (47.8)              |
| **NE, n (%)**  | 6 (13.6)               |
| **ORR (%)**    | 2/38 (5.3%)            |
| **DCR (%)**    | 17/38 (44.7%)          |

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, overall response rate; DCR, disease control rate.

Nal-IRI + 5-FU/l-LV in Advanced Pancreatic Cancer

DOI: 10.1159/000525742
and multivariate analyses. According to univariate analyses, an NLR ≥ 2.7 (p = 0.004) and CRP/Alb ratio ≥ 0.3 (p = 0.023) were significant predictive factors of the OS. According to multivariate analyses, only an NLR ≥ 2.7 was selected as a significant predictive factor of the OS (p = 0.017).

**AEs**

The AEs during nal-IRI + 5-FU/l-LV treatment are summarized in Table 4. AEs were manageable, although gastrointestinal symptoms, such as nausea, loss of appetite, diarrhea, and constipation, were observed. The most frequent grade ≥3 AE was neutropenia, reported in 20% patients, followed by leukopenia, anemia, febrile neutropenia, and loss of appetite.

**Discussion**

The main finding of the present study was that nal-IRI + 5-FU/l-LV therapy was considered to be a useful regimen as second-line or later treatment for unresectable advanced pancreatic cancer, even in clinical practice. An NLR of ≥ 2.7 was a significant predictive factor for the OS.
In a systematic review of 71 studies in patients with unresectable advanced pancreatic cancer who received various second-line treatments, the median OS among all treatments ranged from 4.0 to 5.4 months [19]. Oxaliplatin has been investigated as a second-line treatment for patients with metastatic pancreatic cancer [20, 21]. In the CONKO-3 trial, the median OS was 5.9 months for oxaliplatin + 5-FU/folinic acid as second-line treatment after first-line gemcitabine monotherapy [20]. In the PANCREOX phase 3 study, the median OS was 6.1 months for biweekly modified FOLFOX6 as second-line treatment after first-line gemcitabine monotherapy [21]. In the present study, the median OS was 9.0 months, which was considered to be satisfactory in comparison with the previous regimen of second-line treatment.

The median OS and PFS were reported to be 6.2 (95% CI 4.8–8.4) months and 3.1 (95% CI 2.7–4.2) months, respectively, in the NAPOLI-1 study [11, 12]. A phase II trial in Japan also demonstrated a similar median OS and PFS of 6.3 and 2.7 months, respectively, with a tolerable safety profile [13]. The median OS and PFS in the current study seemed to be slightly better than those in NAPOLI-1 study and the phase II trial in Japan. The ORR and DCR were previously reported to be 17% and 52%, respectively, in the NAPOLI-1 study [11, 12], and a phase II trial in Japan demonstrated a similar ORR (17.5%) and DCR (52.5%) calculated based on the best response [13]. In the present study, the ORR and DCR were 5.3% and 44.7%, respectively, which were slightly worse than those values in previous reports. The American Society of Clinical Oncology Clinical Practice Guidelines for the treatment of metastatic pancreatic cancer recommend nal-IRI + 5-FU/l-LV as second-line therapy in patients previously treated with gemcitabine plus nab-paclitaxel [22], and the current National Comprehensive Cancer Network guidelines for the treatment of pancreatic cancer recommend nal-IRI + 5-FU/l-LV as category 1 second-line therapy for metastatic disease [23].

The NLR showed a significant difference as a predictive factor for the OS and response in the present study. Inflammation has recently been considered to play an essential role in cancer progression. A number of inflammation-based prognostic factors have been developed, including the GPS, mGPS, PLR, NLR, CRP/Alb ratio, and PNI [16–18, 24–26]. Iwai et al. [27] reported that a high NLR might be an independent indicator of a poor prognosis in patients with unresectable pancreatic cancer. In their study, the NLR was the best predictive factor among the GPS, mGPS, PLR, CRP/Alb ratio, and PNI [27]. Although all of these inflammation-based prognostic factors reached statistical significance in their study [27], only the NLR and CRP/Alb ratio reached statistical significance in the present study. In their receiver-operator characteristic analyses for the OS at 6-month follow-up, the AUC area was the greatest for the NLR, followed in descending order by the CRP/Alb ratio, GPS, PNI, mGPS, and PLR [27]. The sequence of the AUC area in the present study was similar to the previous report: NLR, CRP/Alb ratio, mGPS, PNI, and PLR. If the number of patients were increased in our study, not only the NLR and CRP/Alb ratio but also other factors, namely the mGPS, PNI, and PLR, might have also shown statistical significance.

The mechanism underlying the relationship between the NLR and prognosis in patients with unresectable pancreatic cancer remains to be clarified. Neutrophils inhibit the immune response by lymphocytes, natural killer cells, or activated T cells [28, 29], while lymphocytes reflect the immune response of the host to either infection or cancer. Tumor-infiltrating lymphocytes are reported to be associated with a good prognosis in patients with pancreatic ductal adenocarcinoma [30]. Baseline characteristics associated with long-term survivors who survived for more than 1 year in the NAPOLI-1 study [11, 12] were a younger age, better performance status, lower NLR, lower CA19-9 level, and absence of liver metastases. Six of the 44 patients survived for more than 1 year from start of nal-IRI + 5-FU/l-LV treatment in the present study. Although the number of long-term survivors in our study was small, a lower NLR and lower CA19-9 level seemed to be associated with a long-term survival.

Liposomal encapsulation of nal-IRI reduces premature liver metabolism and conversion of irinotecan to the highly active SN-38 metabolite, a topoisomerase I inhibitor [9, 10]. Nal-IRI can prolong the tumor exposure to SN-38 above its antitumor activity threshold in comparison to non-liposomal irinotecan [9, 10]. Nanoparticles of SN-38 were recently reported to activate stimulator of interferon genes (STING) signaling pathway [31]. Interferon and the toll-like receptor 3 signaling pathway are potential pathways involved in the progression of pancreatic intraepithelial neoplasia to cancer and potential targets for pancreatic cancer treatment [32].

AEs were manageable, although gastrointestinal symptoms and blood cell AEs were observed. The most common grade ≥3 AE in this study was neutropenia (20.0%), followed by leukopenia (9.1%) and anemia (6.1%). In the NAPOLI-1 trial, grade ≥3 AEs included neutropenia (15.4%), a decreased white blood cell count (12.0%), and diarrhea (9.4%) [11, 12].
The current study had several limitations. First, this was a retrospective study, and the number of patients was relatively small. Because the number of patients with prior irinotecan-based therapy was small, the effect of a history of irinotecan-based therapy could not be analyzed. Future studies should explore this point.

In conclusion, nal-IRI + 5-FU/l-LV therapy was considered to be a useful regimen as second-line or later treatment for unresectable advanced pancreatic cancer, even in clinical practice. An NLR of ≥ 2.7 was a significant predictive factor. Nal-IRI + 5-FU/l-LV therapy showed a good response with manageable AEs.

Statement of Ethics

This study protocol was approved by the Institutional Ethics Committee of National Hospital Organization Takasaki General Medical Center (2021-61) and each institution. It was conducted in compliance with the 1975 Declaration of Helsinki. Written informed consent was obtained from all patients before treatment, and this study received ethical approval for use of an opt-out methodology.

Conflict of Interest Statement

The authors declare no conflicts of interest in association with this study.

References

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2020;66:7–30.
2 The Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2020. https://gco.iarc.fr/today.
3 Frampton JE. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs. 2020;80(10):1007–18.
4 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14:141.
5 Uccello M, Moschetta M, Mak G, Alam T, Henriquez CM, Arkenau HT. Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA). Curr Oncol. 2018;25:e90–4.
6 Von Hoff DD, Ervin T, Arena FP, Chioorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
7 Comroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécoeurn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
8 Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.
9 Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang TY, Yeh CG, et al. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC Cancer. 2016;16:907.
10 Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271–7.
11 Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–57.
12 Wang-Gillam A, Hubner RA, Sieveke JT, Von Hoff DD, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78–87.
13 Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, et al. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients. Cancer Med. 2020;9:9396–408.
14 Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

Funding Sources

There were no funding supports on this study.

Author Contributions

Hidetoshi Yasuoka, Atsushi Naganuma, and Satoru Kakizaki conceived the study and participated in its design and coordination. Eishin Kurihara, Tsutomu Kobatake, Masashi Iijima, Yuki Tamura, Yuhei Suzuki, Takashi Hoshino, Fumiya Ishida, Hisashi Hosaka, Takeshi Hatanaka, Sachiko Yoshida, Ryu suke Aihara, Norihiro Ishii, and Kenichiho Araki performed data curation. Atsushi Naganuma performed statistical analyses and interpretation. Yasuo Hosouchi, Ken Shirabe, and Toshio Uraoka supervised the study. Hidetoshi Yasuoka, Atsushi Naganuma, and Satoru Kakizaki drafted the text. All the authors have read and approved the final version of the manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article and its supplementary material. Further inquiries can be directed to the corresponding author.
US Department of Health and Human Services. NCI common Terminology Criteria for adverse events (CTCAE), ver 5.0. 2017. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed March 1, 2021).

15 US Department of Health and Human Services. NCI common Terminology Criteria for adverse events (CTCAE), ver 5.0. 2017. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed March 1, 2021).

16 McMillan DC, Crozier JE, Canna K, Angerson WJ, McArindle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22: 881–6.

17 Inoue Y, Iwata T, Okugawa Y, Kawamoto A, Hiro J, Toiyama Y, et al. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology. 2013;84:100–7.

18 Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181–4.

19 Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, et al. Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials. Crit Rev Oncol Hematol. 2015;96:483.

20 Oettle H, Riess H, Stieler JM, Heil G, Schwaner J, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32: 2423.

21 Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiquar M, et al. PANCREOX: a Randomized Phase III Study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34:3914.

22 Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Static pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36: 2545.

23 NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma version 1. 2019. J Natl Compr Canc Netw. 2018.

24 Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466–72.

25 Haruki K, Shiba H, Shirai Y, Horiuchi T, Iwase R, Fujiwara Y, et al. The C-reactive protein/albumin ratio and prognostic nutritional index are strong prognostic indicators of survival in resected pancreatic ductal adenocarcinoma. J Pancreat Cancer. 2017; 3(1):31–6.

26 Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36: 2545.

27 Iwai N, Okuda T, Sakagami J, Harada T, Obara T, Taniguchi M, et al. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Sci Rep. 2020;10: 18758.

28 Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood mononuclear cells. J Immunol. 1987;134:230–4.

29 Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36: 2545.

30 Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466–72.

31 Haruki K, Shiba H, Shirai Y, Horiuchi T, Iwase R, Fujiwara Y, et al. The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg. 2016; 40(9):2254–60.

32 Ikeguchi M, Hanaki T, Endo K, Suzuki K, Nakamura S, Sawata T, et al. C-reactive protein/albumin ratio and prognostic nutritional index are strong prognostic indicators of survival in resected pancreatic ductal adenocarcinoma. J Pancreat Cancer. 2017; 3(1):31–6.